The global asthma therapeutics market size reached US$ 18.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 20.6 Billion by 2028, exhibiting a growth rate (CAGR) of 2.34% during 2023-2028.
Asthma therapeutics refer to various pharmaceutical drugs that are used for the treatment of asthma. Asthma is usually triggered by indoor and outdoor causative agents, including pollution, allergens and dust. These therapeutics are usually bronchodilators and anti-inflammatory drugs, which include corticosteroids, long-acting beta-agonists (LABA), methylxanthine, immunomodulators and leukotriene modifiers. A number of combination therapy drugs are also used that can be inhaled, injected, or orally administered. These drugs expand the passageway into the lungs and enable the movement of air to improve breathing. They also aid in clearing mucus from the lungs that gets coughed out with ease.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Asthma Therapeutics Market Trends:
The increasing prevalence of asthma and other respiratory disorders, along with improvements in the diagnostic technologies, is one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the availability of effective asthma therapeutics is also providing driving the market growth. For instance, asthmatic patients are primarily treated with inhaled corticosteroids and patients with advanced conditions or persistent asthma are treated with target-specific drugs. There is also an extensive demand for monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines. The development of combination therapies for the treatment of respiratory diseases is acting as another growth-inducing factor. Increasing healthcare expenditures, extensive research, and development (R&D) activities in the field of medical sciences and improvements in the healthcare infrastructure are some of the other factors that are expected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global asthma therapeutics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on drug class, product type, treatment type and route of administration.
Breakup by Drug Class:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Anti-Inflammatory Drugs
Bronchodilators
Combination Therapies
Breakup by Product Type:
Inhalers
Dry Powder Inhalers
Metered Dose Inhalers
Soft Mist Inhalers
Nebulizers
Pneumatic Nebulizers
Ultrasonic Nebulizers
Mesh Nebulizers
Breakup by Treatment Type:
Quick-Relief Medications
Long-Term Asthma Control Medications
Breakup by Route of Administration:
Inhalation
Oral
Parenteral
Breakup by Region:
To get more information on the regional analysis of this market,Request Sample
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.
Report Coverage:
Report Features
Details
Base Year of the Analysis
2022
Historical Period
2017-2022
Forecast Period
2023-2028
Units
US$ Billion
Segment Coverage
Drug Class, Product Type, Treatment Type, Route of Administration, Region
Region Covered
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered
AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.
Customization Scope
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
10-12 Weeks
Delivery Format
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global asthma therapeutics market was valued at US$ 18.1 Billion in 2022.
We expect the global asthma therapeutics market to exhibit a CAGR of 2.34% during 2023-2028.
The increasing prevalence of asthma, along with the continuous improvements in the diagnostic
technologies, are primarily driving the global asthma therapeutics market.
The sudden outbreak of the COVID-19 pandemic has led to the rising adoption of asthma therapeutics
for treating asthma, as it is a major side-effect of the coronavirus infection.
Based on the drug class, the global asthma therapeutics market has been segmented into anti-
inflammatory drugs, bronchodilators, and combination therapies. Currently, combination therapies hold
the majority of the total market share.
Based on the product type, the global asthma therapeutics market can be segregated into inhalers and
nebulizers, where inhalers currently exhibit a clear dominance in the market.
Based on the treatment type, the global asthma therapeutics market has been bifurcated into quick-
relief medications and long-term asthma control medications. Currently, long-term asthma control
medications account for the majority of the global market share.
Based on the route of administration, the global asthma therapeutics market can be divided into
inhalation, oral, and parenteral. Among these, inhalation holds the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global asthma therapeutics market include AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.